- Home
- Publications
- Publication Search
- Publication Details
Title
Management of patients with lower-risk myelodysplastic syndromes
Authors
Keywords
-
Journal
Blood Cancer Journal
Volume 12, Issue 12, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-12-14
DOI
10.1038/s41408-022-00765-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Inflammasome Activation in Myeloid Malignancies—Friend or Foe?
- (2022) Nicola Andina et al. Frontiers in Cell and Developmental Biology
- Real‐world experience with luspatercept and predictors of response in myelodysplastic syndromes with ring sideroblasts
- (2022) Faiqa Farrukh et al. AMERICAN JOURNAL OF HEMATOLOGY
- Lenalidomide therapy for primary myelodysplastic syndromes with isolated del(5q): Determinants of response and survival in a real‐world setting
- (2022) Amritpal Singh et al. AMERICAN JOURNAL OF HEMATOLOGY
- International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data
- (2022) Daniel A. Arber et al. BLOOD
- The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
- (2022) Joseph D. Khoury et al. LEUKEMIA
- VEXAS Syndrome: A Novelty in MDS Landscape
- (2022) Marie Templé et al. Diagnostics
- Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide
- (2022) Carmelo Gurnari et al. Blood Cancer Journal
- Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin
- (2021) Alan F. List et al. JOURNAL OF CLINICAL ONCOLOGY
- When Should We Think of Myelodysplasia or Bone Marrow Failure in a Thrombocytopenic Patient? A Practical Approach to Diagnosis
- (2021) Nicolas Bonadies et al. Journal of Clinical Medicine
- Decline in IGF1 in the bone marrow microenvironment initiates hematopoietic stem cell aging
- (2021) Kira Young et al. Cell Stem Cell
- Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes
- (2021) Guillermo Garcia-Manero et al. JOURNAL OF CLINICAL ONCOLOGY
- Prevalence, predictors, and outcomes of clonal hematopoiesis in individuals aged ≥80 years
- (2021) Isabelle A. van Zeventer et al. Blood Advances
- Relationship between clone metrics and clinical outcome in clonal cytopenia
- (2021) Anna Gallì et al. BLOOD
- British Society for Haematology guidelines for the management of adult myelodysplastic syndromes
- (2021) Sally B. Killick et al. BRITISH JOURNAL OF HAEMATOLOGY
- Myelodysplastic Syndromes in the Postgenomic Era and Future Perspectives for Precision Medicine
- (2021) Ioannis Chanias et al. Cancers
- Roxadustat for the treatment of anemia in patients with lower‐risk myelodysplastic syndrome: Open‐label, dose‐selection, lead‐in stage of a phase 3 study
- (2021) David H. Henry et al. AMERICAN JOURNAL OF HEMATOLOGY
- Association of clonal hematopoiesis with chronic obstructive pulmonary disease
- (2021) Peter G. Miller et al. BLOOD
- The wider perspective: twenty years of clinical trials in myelodysplastic syndromes
- (2021) Carolien Duetz et al. BRITISH JOURNAL OF HAEMATOLOGY
- Flow cytometric analysis of myelodysplasia: Pre‐analytical and technical issues—Recommendations from the European LeukemiaNet
- (2021) Vincent H. J. Velden et al. CYTOMETRY PART B-CLINICAL CYTOMETRY
- Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS‐Flow Cytometry Working Group
- (2021) Arjan A. Loosdrecht et al. CYTOMETRY PART B-CLINICAL CYTOMETRY
- When are idiopathic and clonal cytopenias of unknown significance (ICUS or CCUS)?
- (2021) Afaf E. W. G. Osman Hematology-American Society of Hematology Education Program
- Lower risk but high risk
- (2021) Amy E. DeZern Hematology-American Society of Hematology Education Program
- Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 Trial
- (2021) Esther Natalie Oliva et al. Journal of Clinical Medicine
- Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)
- (2020) David P. Steensma et al. BLOOD
- Novel therapies in myelodysplastic syndromes
- (2020) David M. Swoboda et al. CURRENT OPINION IN HEMATOLOGY
- Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1–Risk Myelodysplastic Syndromes
- (2020) Emanuele Angelucci et al. ANNALS OF INTERNAL MEDICINE
- Oral cedazuridine/decitabine: a phase 2, pharmacokinetic/pharmacodynamic, randomized, crossover study in MDS and CMML
- (2020) Guillermo Garcia-Manero et al. BLOOD
- SF3B1-mutant myelodysplastic syndrome as a distinct disease subtype - A Proposal of the International Working Group for the Prognosis of Myelodysplastic Syndromes (IWG-PM)
- (2020) Luca Malcovati et al. BLOOD
- Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective
- (2020) Theo De Witte et al. HAEMATOLOGICA
- Guideline-based indicators for adult patients with myelodysplastic syndromes
- (2020) Kristina Stojkov et al. Blood Advances
- Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion–Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study
- (2020) David P. Steensma et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapy for lower-risk MDS
- (2020) Hetty E. Carraway et al. Hematology-American Society of Hematology Education Program
- Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†☆
- (2020) P. Fenaux et al. ANNALS OF ONCOLOGY
- Roxadustat: First Global Approval
- (2019) Sohita Dhillon DRUGS
- The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes
- (2019) David A. Sallman et al. BLOOD
- Efficacy of granulocyte colony stimulating factor in combination with erythropoiesis stimulating agents for treatment of anemia in patients with lower risk myelodysplastic syndromes: A systematic review
- (2019) Lucas Affentranger et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- What role can next-generation sequencing play in myelodysplastic syndrome care?
- (2019) Nicolas Bonadies et al. Expert Review of Hematology
- The Graft-Versus-Leukemia Effect in AML
- (2019) Connor Sweeney et al. Frontiers in Oncology
- The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005 Study
- (2018) Valeria Santini et al. Clinical Lymphoma Myeloma & Leukemia
- Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes
- (2018) Naval Daver et al. LEUKEMIA
- Diagnostic algorithm for lower-risk myelodysplastic syndromes
- (2018) Ghulam J. Mufti et al. LEUKEMIA
- Pilot trial of K562/GM-CSF whole-cell vaccination in MDS patients
- (2018) Tara M. Robinson et al. LEUKEMIA & LYMPHOMA
- H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers
- (2018) Michael Seiler et al. NATURE MEDICINE
- Prognostic value and clinical feature of SF3B1 mutations in myelodysplastic syndromes: A meta-analysis
- (2018) Yaqiong Tang et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Iron overload in Myelodysplastic Syndromes: Evidence Based Guidelines from the Canadian Consortium on MDS
- (2018) Heather A. Leitch et al. LEUKEMIA RESEARCH
- Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials
- (2018) Uwe Platzbecker et al. BLOOD
- Retuning the immune system in myelodysplastic syndromes: from immunomodulatory approaches to vaccination strategies and non myeloablative hemopoietic cell transplant
- (2018) Claudio Fozza CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Myelodysplastic Syndromes
- (2017) Kim-Hien T. Dao MEDICAL CLINICS OF NORTH AMERICA
- Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease
- (2017) Siddhartha Jaiswal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Azacitidine in Lower‐Risk Myelodysplastic Syndromes: A Meta‐Analysis of Data from Prospective Studies
- (2017) Rami Komrokji et al. ONCOLOGIST
- Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions
- (2017) Peter Valent et al. Oncotarget
- Time-dependent changes in mortality and transformation risk in MDS
- (2016) Michael Pfeilstöcker et al. BLOOD
- Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study
- (2016) Rena Buckstein et al. BRITISH JOURNAL OF HAEMATOLOGY
- Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group
- (2016) Theresia M. Westers et al. HAEMATOLOGICA
- Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group
- (2016) Theresia M. Westers et al. HAEMATOLOGICA
- Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
- (2015) D. P. Steensma et al. BLOOD
- Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion
- (2015) A Toma et al. LEUKEMIA
- Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2014) P. Fenaux et al. ANNALS OF ONCOLOGY
- Comorbidity-Age Index: A Clinical Measure of Biologic Age Before Allogeneic Hematopoietic Cell Transplantation
- (2014) Mohamed L. Sorror et al. JOURNAL OF CLINICAL ONCOLOGY
- Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
- (2014) Siddhartha Jaiswal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet
- (2013) L. Malcovati et al. BLOOD
- Revised International Prognostic Scoring System for Myelodysplastic Syndromes
- (2012) P. L. Greenberg et al. BLOOD
- Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group
- (2012) T M Westers et al. LEUKEMIA
- SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value
- (2011) M. M. Patnaik et al. BLOOD
- Immunosuppressive Therapy for Patients With Myelodysplastic Syndrome: A Prospective Randomized Multicenter Phase III Trial Comparing Antithymocyte Globulin Plus Cyclosporine With Best Supportive Care—SAKK 33/99
- (2010) Jakob R. Passweg et al. JOURNAL OF CLINICAL ONCOLOGY
- Factors Affecting Response and Survival in Patients With Myelodysplasia Treated With Immunosuppressive Therapy
- (2008) Elaine M. Sloand et al. JOURNAL OF CLINICAL ONCOLOGY
- Relationship of Treatment-Related Cytopenias and Response to Lenalidomide in Patients With Lower-Risk Myelodysplastic Syndromes
- (2008) Mikkael A. Sekeres et al. JOURNAL OF CLINICAL ONCOLOGY
- Characteristics of US Patients with Myelodysplastic Syndromes: Results of Six Cross-sectional Physician Surveys
- (2008) Mikkael A. Sekeres et al. JNCI-Journal of the National Cancer Institute
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started